292 related articles for article (PubMed ID: 21225912)
21. Severe life threatening neurotoxicity in a child with acute lymphoblastic leukemia receiving posaconazole and vincristine.
Jain S; Kapoor G
Pediatr Blood Cancer; 2010 May; 54(5):783. PubMed ID: 20205256
[No Abstract] [Full Text] [Related]
22. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia.
Diouf B; Crews KR; Lew G; Pei D; Cheng C; Bao J; Zheng JJ; Yang W; Fan Y; Wheeler HE; Wing C; Delaney SM; Komatsu M; Paugh SW; McCorkle JR; Lu X; Winick NJ; Carroll WL; Loh ML; Hunger SP; Devidas M; Pui CH; Dolan ME; Relling MV; Evans WE
JAMA; 2015 Feb; 313(8):815-23. PubMed ID: 25710658
[TBL] [Abstract][Full Text] [Related]
23. Apparent high CYP3A5 expression is required for significant metabolism of vincristine by human cryopreserved hepatocytes.
Dennison JB; Mohutsky MA; Barbuch RJ; Wrighton SA; Hall SD
J Pharmacol Exp Ther; 2008 Oct; 327(1):248-57. PubMed ID: 18650247
[TBL] [Abstract][Full Text] [Related]
24. Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant Recipients.
Trofe-Clark J; Brennan DC; West-Thielke P; Milone MC; Lim MA; Neubauer R; Nigro V; Bloom RD
Am J Kidney Dis; 2018 Mar; 71(3):315-326. PubMed ID: 29162334
[TBL] [Abstract][Full Text] [Related]
25. Mir-pharmacogenetics of Vincristine and peripheral neurotoxicity in childhood B-cell acute lymphoblastic leukemia.
Gutierrez-Camino Á; Umerez M; Martin-Guerrero I; García de Andoin N; Santos B; Sastre A; Echebarria-Barona A; Astigarraga I; Navajas A; Garcia-Orad A
Pharmacogenomics J; 2018 Dec; 18(6):704-712. PubMed ID: 29282364
[TBL] [Abstract][Full Text] [Related]
26. Impact of Pharmacogenetics on Intravenous Tacrolimus Exposure and Conversions to Oral Therapy.
Pasternak AL; Marcath LA; Li Y; Nguyen V; Gersch CL; Rae JM; Frame D; Scappaticci G; Kidwell KM; Hertz DL
Transplant Cell Ther; 2022 Jan; 28(1):19.e1-19.e7. PubMed ID: 34583027
[TBL] [Abstract][Full Text] [Related]
27. Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on dose-adjusted plasma levels of carbamazepine in epileptic patients in South Indian population.
Ganesapandian M; Ramasamy K; Adithan S; Narayan SK
Indian J Pharmacol; 2019; 51(6):384-388. PubMed ID: 32029960
[TBL] [Abstract][Full Text] [Related]
28. Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia.
Hartman A; van Schaik RH; van der Heiden IP; Broekhuis MJ; Meier M; den Boer ML; Pieters R
Leuk Res; 2010 Feb; 34(2):154-9. PubMed ID: 19467705
[TBL] [Abstract][Full Text] [Related]
29. Fluoroquinolone prophylaxis does not increase risk of neuropathy in children with acute lymphoblastic leukemia.
Karol SE; Sun Y; Tang L; Pui CH; Ferrolino J; Allison KJ; Cross SJ; Evans WE; Crews KR; Jeha S; Wolf J
Cancer Med; 2020 Sep; 9(18):6550-6555. PubMed ID: 32710497
[TBL] [Abstract][Full Text] [Related]
30. Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia.
Ceppi F; Langlois-Pelletier C; Gagné V; Rousseau J; Ciolino C; De Lorenzo S; Kevin KM; Cijov D; Sallan SE; Silverman LB; Neuberg D; Kutok JL; Sinnett D; Laverdière C; Krajinovic M
Pharmacogenomics; 2014 Jun; 15(8):1105-16. PubMed ID: 25084203
[TBL] [Abstract][Full Text] [Related]
31. Severe Vincristine-related Neurotoxicity in 5 Patients With Pediatric Acute Lymphoblastic Leukemia Requiring Discontinuation of Vincristine: A Description of Long-term Outcome.
Egan-Sherry D; Bhuta R; Cole PD; Gennarini LM; Kahn JM; Sulis ML; DeNardo BD; Welch JJG
J Pediatr Hematol Oncol; 2021 Oct; 43(7):e997-e999. PubMed ID: 34001785
[TBL] [Abstract][Full Text] [Related]
32. Genetic factors influencing the development of vincristine-induced neurotoxicity.
Pozzi E; Fumagalli G; Chiorazzi A; Canta A; Cavaletti G
Expert Opin Drug Metab Toxicol; 2021 Feb; 17(2):215-226. PubMed ID: 33283553
[No Abstract] [Full Text] [Related]
33. Effect of pyridoxine plus pyridostigmine treatment on vincristine-induced peripheral neuropathy in pediatric patients with acute lymphoblastic leukemia: a single-center experience.
Aydin Köker S; Gözmen S; Demirağ B; Ünalp A; Karapinar TH; Oymak Y; Gürbüz G; Öner Eİ; Vergin RC
Neurol Sci; 2021 Sep; 42(9):3681-3686. PubMed ID: 33439396
[TBL] [Abstract][Full Text] [Related]
34. Genetic polymorphisms in candidate genes are not associated with increased vincristine-related peripheral neuropathy in Arab children treated for acute childhood leukemia: a single institution study.
Zgheib NK; Ghanem KM; Tamim H; Aridi C; Shahine R; Tarek N; Saab R; Abboud MR; El-Solh H; Muwakkit SA
Pharmacogenet Genomics; 2018 Aug; 28(8):189-195. PubMed ID: 30119132
[TBL] [Abstract][Full Text] [Related]
35. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
Deininger KM; Vu A; Page RL; Ambardekar AV; Lindenfeld J; Aquilante CL
Clin Transplant; 2016 Sep; 30(9):1074-81. PubMed ID: 27314545
[TBL] [Abstract][Full Text] [Related]
36. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation.
Hesselink DA; Bouamar R; Elens L; van Schaik RH; van Gelder T
Clin Pharmacokinet; 2014 Feb; 53(2):123-39. PubMed ID: 24249597
[TBL] [Abstract][Full Text] [Related]
37. Pharmacogenetic association with neurotoxicity in Hispanic children with acute lymphoblastic leukaemia.
McClain CA; Bernhardt MB; Berger A; Bernini JC; Marquez-Do D; Winslow R; Scheurer ME; Schafer ES
Br J Haematol; 2018 Jun; 181(5):684-687. PubMed ID: 28419449
[No Abstract] [Full Text] [Related]
38. Genetic polymorphisms and vincristine-induced peripheral neuropathy in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone therapy.
Sawaki A; Miyazaki K; Yamaguchi M; Takeuchi T; Kobayashi K; Imai H; Tawara I; Ono R; Nosaka T; Katayama N
Int J Hematol; 2020 May; 111(5):686-691. PubMed ID: 31993939
[TBL] [Abstract][Full Text] [Related]
39. Identification of a less toxic vinca alkaloid derivative for use as a chemotherapeutic agent, based on in silico structural insights and metabolic interactions with CYP3A4 and CYP3A5.
Saba N; Seal A
J Mol Model; 2018 Mar; 24(4):82. PubMed ID: 29502215
[TBL] [Abstract][Full Text] [Related]
40. Prospective assessment of vincristine-induced peripheral neuropathy in paediatric acute lymphoblastic leukemia.
Li T; Kandula T; Cohn RJ; Kiernan MC; Park SB; Farrar MA
Clin Neurophysiol; 2023 Oct; 154():157-168. PubMed ID: 37633123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]